BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

948 related articles for article (PubMed ID: 17214731)

  • 21. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
    Singh F; Lebwohl MG
    J Am Acad Dermatol; 2004 Oct; 51(4):570-3. PubMed ID: 15389192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Folliculotropic mycosis fungoides.
    Hunzeker CM; Fangman W; Latkowski JA
    Dermatol Online J; 2007 Jan; 13(1):5. PubMed ID: 17511938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A patient with clinicopathologic features of small plaque parapsoriasis presenting later with plaque-stage mycosis fungoides: report of a case and comparative retrospective study of 27 cases of "nonprogressive" small plaque parapsoriasis.
    Belousova IE; Vanecek T; Samtsov AV; Michal M; Kazakov DV
    J Am Acad Dermatol; 2008 Sep; 59(3):474-82. PubMed ID: 18694680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bexarotene salvage therapy in a patient with refractory erythrodermic mycosis fungoides after failure on interferon/PUVA and methotrexate.
    Dalle S; Thomas L
    Dermatol Clin; 2008 Jan; 26 Suppl 1():39-41. PubMed ID: 18405186
    [No Abstract]   [Full Text] [Related]  

  • 25. Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides.
    Lokitz ML; Wong HK
    Photodermatol Photoimmunol Photomed; 2007 Dec; 23(6):255-7. PubMed ID: 17986063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Folliculotropic mycosis fungoides responding to bexarotene gel.
    Walling HW; Swick BL; Gerami P; Scupham RK
    J Drugs Dermatol; 2008 Feb; 7(2):169-71. PubMed ID: 18335654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Unilesional plaque-type mycosis fungoides: 3 cases].
    Verret JL; Rousselet MC; Peria P
    Ann Dermatol Venereol; 1997; 124(8):527-30. PubMed ID: 9740844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides.
    Papadavid E; Antoniou C; Nikolaou V; Siakantaris M; Vassilakopoulos TP; Stratigos A; Stavrianeas N; Katsambas A
    Am J Clin Dermatol; 2008; 9(3):169-73. PubMed ID: 18429646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma.
    McGinnis KS; Shapiro M; Vittorio CC; Rook AH; Junkins-Hopkins JM
    Arch Dermatol; 2003 Jun; 139(6):771-5. PubMed ID: 12810509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained remission of treatment-resistant cutaneous T-cell lymphoma with oral bexarotene.
    Mehlmauer MA
    Cutis; 2004 Jun; 73(6):417-20. PubMed ID: 15224787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate.
    Steinhoff M; Beyer M; Roewert-Huber J; Lukowsky A; Assaf C; Sterry W
    J Am Acad Dermatol; 2008 May; 58(5 Suppl 1):S88-91. PubMed ID: 18489056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD8-positive granulomatous mycosis fungoides: a case report with review of the literature.
    Ishida M; Hotta M; Takikita-Suzuki M; Kojima F; Okabe H
    J Cutan Pathol; 2010 Oct; 37(10):1072-6. PubMed ID: 20579213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Large cell transformation mimicking regional lymphomatoid papulosis in a patient with mycosis fungoides.
    Nakahigashi K; Ishida Y; Matsumura Y; Kore-Eda S; Ohmori K; Fujimoto M; Yamashita K; Kotani H; Sakurai T; Miyachi Y
    J Dermatol; 2008 May; 35(5):283-8. PubMed ID: 18477228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple keratoacanthomas in a young woman: report of a case emphasizing medical management and a review of the spectrum of multiple keratoacanthomas.
    Feldman RJ; Maize JC
    Int J Dermatol; 2007 Jan; 46(1):77-9. PubMed ID: 17214727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mycosis fungoides: cutaneous T-cell lymphoma.
    Zaim MT; Grinkemeyer MD
    Am Fam Physician; 1991 May; 43(5):1703-7. PubMed ID: 2021105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Granulomatous mycosis fungoides histologically simulating cutaneous sarcoidosis].
    Maillard H; Croué A; François S; Verret JL
    Ann Dermatol Venereol; 1998 Dec; 125(12):912-5. PubMed ID: 9922868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of refractory stage IV mycosis fungoides with bexarotene monotherapy.
    Otremba B
    Dermatol Clin; 2008 Jan; 26 Suppl 1():51-2. PubMed ID: 18405188
    [No Abstract]   [Full Text] [Related]  

  • 38. The optimal use of bexarotene in cutaneous T-cell lymphoma.
    Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
    Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
    Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD
    Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene.
    Talpur R; Duvic M
    Clin Lymphoma Myeloma; 2006 May; 6(6):488-92. PubMed ID: 16796781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.